STERIS (STE) has just refreshed its board, appointing bioMérieux CEO Pierre Boulud following the planned retirement of long-serving director Richard C. Breeden. The move puts governance and global healthcare experience in focus.

At a share price of $213.70, STERIS has seen a 15.3% decline in its 90 day share price return and a 14.5% drop year to date. Its 1 year total shareholder return decline of 4.4% and 5 year total shareholder return of 12.5% suggest longer term holders have experienced more moderate results. Recent weakness points to fading short term momentum, while the board refresh and upcoming earnings keep investor attention on potential shifts in growth expectations and risk perception.

If this board reshuffle has you thinking about where healthcare could head next, it might be worth widening your search with a screener focused on 35 healthcare AI stocks

With STERIS trading at $213.70 alongside an indicated intrinsic discount and a sizable gap to analyst targets, the real question for you is whether current weakness is a chance to buy in, or whether the market already reflects prospects for future growth.

Most Popular Narrative: 23.5% Undervalued

With STERIS last closing at $213.70 and the most followed fair value estimate at $279.29, the current gap centers attention on what assumptions sit behind that valuation.

Continued expansion of STERIS's consumables and services segments with high recurring revenue and margin visibility positions the company to benefit from increasing healthcare expenditures and adoption of best practice infection control standards, supporting both revenue and margin expansion.

Curious what kind of revenue mix, profit margins and future earnings power need to hold up for that valuation to make sense? The narrative leans heavily on recurring income, disciplined share repurchases and a future earnings multiple that assumes the market will keep paying a premium.

Result: Fair Value of $279.29 (UNDERVALUED)

However, this hinges on key assumptions, and pressure from tariffs on metals and healthcare reimbursement changes could easily unsettle margins and capital spending plans.

Another Angle on Valuation

The narrative leans on future earnings power and a premium P/E. Yet today STERIS trades on a P/E of 29.6x versus a fair ratio of 24.1x, the US Medical Equipment industry at 23.9x and peers at 20.2x. That richer multiple points to valuation risk if sentiment cools.

To see what the numbers say about this price, take a closer look at our valuation breakdown, starting with the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on STERIS clearly mixed, now is a good time to look at the numbers yourself, weigh the trade offs, and test how comfortable you are with the current valuation and growth story. To see what investors are optimistic about, review the 4 key rewards

Looking for more investment ideas?

If you stop with just one stock, you could miss other opportunities that better match your goals, risk comfort and income needs. Broaden your search with these focused ideas.

• Target potential mispricings by scanning for quality companies trading below their estimated worth using the 51 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks in the 12 dividend fortresses that combine high yields with an emphasis on resilience.
• Dial down risk by concentrating on financially sound companies through the 71 resilient stocks with low risk scores so your portfolio is built on sturdier footing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.